<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0346989" disease_type="Neoplastic Process" abbrv="">Peritoneal metastases</z:e> (PM) are a common presentation for patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>), and the median survival of patients with PM is approximately one year </plain></SENT>
<SENT sid="1" pm="."><plain>In a majority of patients, the disease remains limited to the peritoneal cavity </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, investigators have applied cytoreductive surgery (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRS</z:e>) and heated perioperative chemotherapy (HIPEC) as a standard approach for selected patients with PM from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>These investigators have demonstrated a very promising long-term survival in a subset of patients with a limited amount of isolated peritoneal <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>This paper presents the data that supports <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRS</z:e> and HIPEC as a treatment option for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients with PM </plain></SENT>
<SENT sid="5" pm="."><plain>These results of treatment are compared and contrasted to the results that can be expected with systemic chemotherapy alone </plain></SENT>
</text></document>